# Tenet Healthcare Corp: Form 10-Q for the period ended Mar 31, 2019

- Company: [Tenet Healthcare Corp](/companies/thc.md) (CIK 70318)
- Form: 10-Q
- Filed: 2019-04-29
- Accepted by EDGAR: Apr 29, 2019, 16:22 ET
- Period: 2019-03-31
- Accession: 0000070318-19-000024
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/70318/000007031819000024/thc-20190331x10xq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/70318/000007031819000024/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 3 months, 2019-01-01 to 2019-03-31 | $371.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-01-01 to 2019-03-31 | $251.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2019-01-01 to 2019-03-31 | $17.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-01-01 to 2019-03-31 | $65.0m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2019-01-01 to 2019-03-31 | −$0.18 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-01-01 to 2019-03-31 | −$0.18 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-01-01 to 2019-03-31 | 102,788,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2019-01-01 to 2019-03-31 | $10.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2019-01-01 to 2019-03-31 | $192.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-03-31 | $252.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-03-31 | $4.58bn | us-gaap:AssetsCurrent |
| Total assets | at 2019-03-31 | $23.16bn | us-gaap:Assets |
| Current liabilities | at 2019-03-31 | $3.73bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-03-31 | $21.05bn | us-gaap:Liabilities |
| Shareholders' equity | at 2019-03-31 | −$134.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 108,454 characters.

### INTRODUCTION TO MANAGEMENT’S DISCUSSION AND ANALYSIS

The purpose of this section, Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), is to provide a narrative explanation of our financial statements that enables investors to better understand our business, to enhance our overall financial disclosures, to provide the context within which our financial information may be analyzed, and to provide information about the quality of, and potential variability of, our financial condition, results of operations and cash flows. Our Hospital Operations and other segment is comprised of our acute care and specialty hospitals, ancillary outpatient facilities, urgent care centers, microhospitals and physician practices. Our Ambulatory Care segment is comprised of the operations of our USPI Holding Company, Inc. (“USPI”), in which we own a 95% interest, and included nine European Surgical Partners Limited (“Aspen”) facilities until their divestiture effective August 17, 2018. At March 31, 2019, USPI had interests in 252 ambulatory surgery centers, 36 urgent care centers, 23 imaging centers and 23 surgical hospitals in 27 states. Our Conifer segment provides healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems, as well as individual hospitals, physician practices, self-insured organizations, health plans and other entities, through our Conifer Holdings, Inc. (“Conifer”) subsidiary. Nearly all of the services comprising the operations of our Conifer segment are provided directly by Conifer Health Solutions, LLC, in which we owned 76.2% as of March 31, 2019, or by one of its direct or indirect wholly owned subsidiaries. MD&A, which should be read in conjunction with the accompanying Condensed Consolidated Financial Statements, includes the following sections:

- Management Overview
- Forward-Looking Statements
- Sources of Revenue for Our Hospital Operations and Other Segment
- Results of Operations
- Liquidity and Capital Resources
- Off-Balance Sheet Arrangements
- Critical Accounting Estimates

Unless otherwise indicated, all financial and statistical information included in MD&A relates to our continuing operations, with dollar amounts expressed in millions (except per adjusted patient admission and per adjusted patient day amounts). Continuing operations information includes the results of (i) our same 65 hospitals operated throughout the three months ended March 31, 2019 and 2018, (ii) two Philadelphia-area hospitals, which we divested effective January 11, 2018, (iii) MacNeal Hospital, which we divested effective March 1, 2018, (iv) Des Peres Hospital, which we divested effective May 1, 2018, (v) three Chicago-area hospitals, which we divested effective January 28, 2019, and (vi) Aspen's nine facilities, which we divested August 17, 2018. Continuing operations information excludes the results of our hospitals and other businesses that have been classified as discontinued operations for accounting purposes.

### MANAGEMENT OVERVIEW

### TRENDS AND STRATEGIES

The healthcare industry, in general, and the acute care hospital business, in particular, have been experiencing significant regulatory uncertainty based, in large part, on administrative, legislative and judicial efforts to significantly modify or repeal and potentially replace the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (“Affordable Care Act” or “ACA”). It is difficult to predict the full impact of regulatory uncertainty on our future revenues and operations. In addition, we believe that several key trends are shaping the demand for healthcare services: (1) consumers, employers and insurers are actively seeking lower-cost solutions and better value as they focus more on healthcare spending; (2) patient volumes are shifting from inpatient to outpatient settings due to technological advancements and demand for care that is more convenient, affordable and accessible; (3) the industry is migrating to value-based payment models with government and private payers shifting risk to providers; and (4) consolidation continues across the entire healthcare sector.

*Driving Growth in Our Hospital Systems—*We are committed to better positioning our hospital systems and competing more effectively in the ever-evolving healthcare environment. We are focused on improving operational effectiveness, increasing capital efficiency and margins, enhancing patient satisfaction, growing our higher-acuity inpatient service lines, expanding patient access points, and exiting service lines, businesses and markets that we believe are no longer a core part of our long-term growth strategy. We have undertaken enterprise-wide cost reduction initiatives, comprised primarily of workforce reductions (including streamlining corporate overhead and centralized support functions), the renegotiation of contracts with suppliers and vendors, and the consolidation of office locations. In conjunction with these initiatives, we incurred restructuring charges related to employee severance payments of $7 million in the three months ended March 31, 2019, and we expect to incur additional such restructuring charges in the remainder of 2019.

*Improving the Customer Care Experience—*As consumers continue to become more engaged in managing their health, we recognize that understanding what matters most to them and earning their loyalty is imperative to our success. As such, we have enhanced our focus on treating our patients as traditional customers by: (1) establishing networks of physicians and facilities that provide convenient access to services across the care continuum; (2) expanding service lines aligned with growing community demand, including a focus on chronic disease patients; (3) offering greater affordability and predictability, including simplified admissions and discharge procedures, particularly in our outpatient centers; (4) improving our culture of service; and (5) creating health and benefit programs, patient education and health literacy materials that are customized to the needs of the communities we serve. Through these efforts, we intend to improve the customer care experience in every part of our operations.

*Expansion of Our Ambulatory Care Segment—*We remain focused on opportunities to expand our Ambulatory Care segment through organic growth, building new outpatient centers, corporate development activities and strategic partnerships. We believe USPI’s surgery centers and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in medical technology, and due to the lower cost structure and greater efficiencies that are attainable at a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to increase. In addition, we have continued to grow our imaging and urgent care businesses through USPI to reflect our broader strategies to (1) offer more services to patients, (2) broaden the capabilities we offer to healthcare systems and physicians, and (3) expand into faster-growing, less capital intensive, higher-margin businesses. Historically, our outpatient services have generated significantly higher margins for us than inpatient services.

*Exploration of Strategic Alternatives for Conifer While Continuing to Drive Conifer’s Growth—*We previously announced a number of actions to support our goals of improving financial performance and enhancing shareholder value, including the exploration of a potential sale of Conifer. In addition to a potential sale, we are considering other strategic alternatives for Conifer, such as a merger, a tax efficient spin-off or a combination of alternative transactions. There can be no assurance that this process will result in any transaction.

Conifer serves approximately 730 Tenet and non-Tenet hospital and other clients nationwide. In addition to providing revenue cycle management services to healthcare systems and physicians, Conifer provides support to both providers and self-insured employers seeking assistance with clinical integration, financial risk management and population health management. Conifer remains focused on driving growth by continuing to market and expand its revenue cycle management and value-based care solutions businesses.

*Improving Profitability—*We are focused on growing patient volumes and effective cost management as a means to improve profitability. We believe our inpatient admissions have been constrained in recent years by increased competition, utilization pressure by managed care organizations, new delivery models that are designed to lower the utilization of acute care hospital services, the effects of higher patient co-pays, co-insurance amounts and deductibles, changing consumer behavior, and adverse economic conditions and demographic trends in certain of our markets. However, we also believe that emphasis on higher-demand clinical service lines (including outpatient services), focus on expanding our ambulatory care business, cultivation of our culture of service, participation in Medicare Advantage health plans that are experiencing higher growth rates than traditional Medicare plans, and contracting strategies that create shared value with payers should help us grow our patient volumes over time. In 2019, we are continuing to explore new opportunities to enhance efficiency, including further integration of enterprise-wide centralized support functions, outsourcing certain functions unrelated to direct patient care, and reducing clinical and vendor contract variation.

*Reducing Our Leverage—*All of our outstanding long-term debt has a fixed rate of interest, except for outstanding borrowings under our revolving credit facility, and the maturity dates of our notes are staggered from 2020 through 2031. Although we believe that our capital structure minimizes the near-term impact of increased interest rates, and the staggered maturities of our debt allow us to refinance our debt over time, it is nonetheless our long-term objective to lower our ratio of debt-to-Adjusted EBITDA, primarily through more efficient capital allocation and Adjusted EBITDA growth, which should lower our refinancing risk and increase the potential for us to continue to use lower rate secured debt to refinance portions of our higher rate unsecured debt.

Our ability to execute on our strategies and respond to the aforementioned trends is subject to a number of risks and uncertainties that may cause actual results to be materially different from expectations. For information about risks and uncertainties that could affect our results of operations, see the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report on Form 10-K for the year ended December 31, 2018 (“Annual Report”).

### RESULTS OF OPERATIONS—OVERVIEW

The following tables show certain selected operating statistics for our continuing operations, which includes the results of (i) our same 65 hospitals operated throughout the three months ended March 31, 2019 and 2018, (ii) two Philadelphia-area hospitals, which we divested effective January 11, 2018, (iii) MacNeal Hospital, which we divested effective March 1, 2018, (iv) Des Peres Hospital, which we divested effective May 1, 2018, and (v) three Chicago-area hospitals, which we divested effective January 28, 2019. The following tables also show information about facilities in our Ambulatory Care segment that we control and, therefore, consolidate. The results of our former Aspen facilities, which we divested on August 17, 2018, are also included. We believe this information is useful to investors because it reflects our current portfolio of operations and the recent trends we are experiencing with respect to volumes, revenues and expenses.

| Selected Operating Statistics Hospital Operations and other – hospitals and related outpatient facilities | Continuing Operations Three Months Ended March 31, 2019 | 2018 | Increase (Decrease) |  |
| --- | ---: | ---: | ---: | ---: |
| Number of hospitals (at end of period) | 65 | 69 | (4) | (1) |
| Total admissions | 174,726 | 182,306 | (4.2)% |  |
| Adjusted patient admissions(2) | 308,133 | 320,868 | (4.0)% |  |
| Paying admissions (excludes charity and uninsured) | 164,793 | 172,490 | (4.5)% |  |
| Charity and uninsured admissions | 9,933 | 9,816 | 1.2% |  |
| Emergency department visits | 657,449 | 697,001 | (5.7)% |  |
| Total surgeries | 103,013 | 110,231 | (6.5)% |  |
| Patient days — total | 822,079 | 858,648 | (4.3)% |  |
| Adjusted patient days(2) | 1,420,170 | 1,486,139 | (4.4)% |  |
| Average length of stay (days) | 4.70 | 4.71 | (0.2)% |  |
| Average licensed beds | 17,455 | 18,685 | (6.6)% |  |
| Utilization of licensed beds(3) | 52.3% | 51.1% | 1.2% | (1) |
| Total visits | 1,714,392 | 1,842,539 | (7.0)% |  |
| Paying visits (excludes charity and uninsured) | 1,603,712 | 1,725,976 | (7.1)% |  |
| Charity and uninsured visits | 110,680 | 116,563 | (5.0)% |  |
| **Ambulatory Care** |  |  |  |  |
| Total consolidated facilities (at end of period) | 226 | 230 | (4) | (1) |
| Total cases | 496,988 | 495,301 | 0.3% |  |

(1) The change is the difference between the 2019 and 2018 amounts shown.

(2) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

(3) Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

Total admissions decreased by 7,580, or 4.2%, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018, and total surgeries decreased by 7,218, or 6.5%, in the 2019 period compared to the 2018 period. Our emergency department visits decreased 5.7% in the three months ended March 31, 2019 compared to the same period in the prior year. Our volumes from continuing operations in the three months ended March 31, 2019 compared to the three months ended March 31, 2018 were negatively affected by the sale of two Philadelphia-area hospitals and affiliated operations effective January 11, 2018, the sale of MacNeal Hospital and affiliated operations effective March 1, 2018, the sale of Des Peres Hospital and affiliated operations effective May 1, 2018, and the sale of three Chicago-area hospitals and affiliated operations effective January 28, 2019. Our Ambulatory Care total cases increased 0.3% in the three months ended March 31, 2019 compared to the 2018 period. Our Ambulatory care volumes were negatively affected by the sale of Aspen effective August 17, 2018.

| Revenues Net operating revenues | Continuing Operations Three Months Ended March 31, 2019 | 2018 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Hospital Operations and other prior to inter-segment eliminations | $3,862 | $3,947 | (2.2)% |
| Ambulatory Care | 480 | 498 | (3.6)% |
| Conifer | 349 | 404 | (13.6)% |
| Inter-segment eliminations | (146) | (150) | (2.7)% |
| **Total** | **$4,545** | **$4,699** | **(3.3)%** |

Net operating revenues decreased by $154 million, or 3.3%, in the three months ended March 31, 2019 compared to the same period in 2018, primarily due to the sale and closure of facilities described above. For our Hospital Operations and other segment, the impact of lower volumes on net operating revenues was partially mitigated by improved managed care pricing.

Our accounts receivable days outstanding (“AR Days”) from continuing operations were 58.6 days at March 31, 2019 and 56.5 days at December 31, 2018, compared to our target of less than 55 days. This calculation includes our Hospital Operations and other contract assets, and excludes (i) two Philadelphia-area hospitals, which we divested effective January 11, 2018, (ii) MacNeal Hospital, which we divested effective March 1, 2018, (iii) Des Peres Hospital, which we divested effective May 1, 2018, (iv) three Chicago-area hospitals, which we divested effective January 28, 2019, and (v) our California provider fee revenues.

| Selected Operating Expenses Hospital Operations and other | Continuing Operations Three Months Ended March 31, 2019 | 2018 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Salaries, wages and benefits | $1,815 | $1,840 | (1.4)% |
| Supplies | 641 | 666 | (3.8)% |
| Other operating expenses | 928 | 889 | 4.4% |
| Total | $3,384 | $3,395 | (0.3)% |
| **Ambulatory Care** |  |  |  |
| Salaries, wages and benefits | $153 | $162 | (5.6)% |
| Supplies | 99 | 106 | (6.6)% |
| Other operating expenses | 82 | 92 | (10.9)% |
| Total | $334 | $360 | (7.2)% |
| **Conifer** |  |  |  |
| Salaries, wages and benefits | $185 | $225 | (17.8)% |
| Supplies | 1 | 2 | (50.0)% |
| Other operating expenses | 64 | 79 | (19.0)% |
| Total | $250 | $306 | (18.3)% |
| **Total** |  |  |  |
| Salaries, wages and benefits | $2,153 | $2,227 | (3.3)% |
| Supplies | 741 | 774 | (4.3)% |
| Other operating expenses | 1,074 | 1,060 | 1.3% |
| Total | $3,968 | $4,061 | (2.3)% |
| Rent/lease expense(1) |  |  |  |
| Hospital Operations and other | $59 | $59 | —% |
| Ambulatory Care | 20 | 20 | —% |
| Conifer | 3 | 4 | (25.0)% |
| Total | $82 | $83 | (1.2)% |

(1) Included in other operating expenses.

| Selected Operating Expenses per Adjusted Patient Admission Hospital Operations and other | Continuing Operations Three Months Ended March 31, 2019 | 2018 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Salaries, wages and benefits per adjusted patient admission(1) | $5,888 | $5,727 | 2.8% |
| Supplies per adjusted patient admission(1) | 2,078 | 2,079 | —% |
| Other operating expenses per adjusted patient admission(1) | 3,013 | 2,755 | 9.4% |
| Total per adjusted patient admission | $10,979 | $10,561 | 4.0% |

(1) Calculation excludes the expenses from our health plan businesses. Adjusted patient admissions represents actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

Salaries, wages and benefits per adjusted patient admission increased 2.8% in the three months ended March 31, 2019 compared to the same period in 2018. This change is primarily due to the effect of lower volumes on operating leverage due to certain fixed staffing costs and annual merit increases for certain of our employees, partially offset by decreased health benefits costs and the impact of previously announced workforce reductions as part of our enterprise-wide cost reduction initiatives in the three months ended March 31, 2019 compared to the three months ended March 31, 2018.

Supplies expense per adjusted patient admission remained substantially the same in the three months ended March 31, 2019 compared to the three months ended March 31, 2018. Supplies expense was impacted unfavorably by growth in our higher acuity supply-intensive surgical services offset by the favorable impact of the group-purchasing strategies and supplies-management services we utilize to reduce costs.

Other operating expenses per adjusted patient admission increased by 9.4% in the three months ended March 31, 2019 compared to the prior-year period. This increase is primarily due to higher medical fees per adjusted patient admission, the effect of lower volumes on operating leverage due to certain fixed costs, and increased malpractice expense for our Hospital Operations and other segment, which was $38 million higher in the 2019 period compared to the 2018 period. The 2019 period included an unfavorable adjustment of approximately $7 million from a 28 basis point decrease in the interest rate used to estimate the discounted present value of projected future malpractice liabilities compared to a favorable adjustment of approximately $10 million from a 35 basis point increase in the interest rate in the 2018 period.

### LIQUIDITY AND CAPITAL RESOURCES OVERVIEW

Cash and cash equivalents were $252 million at March 31, 2019 compared to $411 million at December 31, 2018.

Significant cash flow items in the three months ended March 31, 2019 included:

- Net cash provided by operating activities before interest, taxes, discontinued operations and restructuring charges, acquisition-related costs, and litigation costs and settlements of $193 million;
- Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements of $32 million;
- Capital expenditures of $192 million;
- Proceeds from the sales of facilities and other assets in continuing operations of $41 million;
- Interest payments of $158 million;
- $1.5 billion of proceeds from the issuance of $1.5 billion aggregate principal amount of 6.250% senior secured second lien notes due 2027;
- $310 million of payments to purchase $300 million aggregate principal amount of our outstanding 6.750% senior notes due 2020;
- $778 million of payments to purchase $750 million aggregate principal amount of our outstanding 7.500% senior secured second lien notes due 2022;
- $468 million to repay $468 million aggregate principal amount of our outstanding 5.500% senior unsecured notes due 2019 upon maturity; and
- $74 million of distributions paid to noncontrolling interests.

Net cash provided by operating activities was $10 million in the three months ended March 31, 2019 compared to $113 million in the three months ended March 31, 2018. Key factors contributing to the change between the 2019 and 2018 periods include the following:

- Decreased net cash of $25 million related to the California provider fee program due to the timing of payments from the state; and
- The timing of other working capital items.

### FORWARD-LOOKING STATEMENTS

This report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements, other than statements of historical or present facts, that address activities, events, outcomes, business strategies and other matters that we plan, expect, intend, assume, believe, budget, predict, forecast, project, target, estimate or anticipate (and other similar expressions) will, should or may occur in the future are forward-looking statements, including (but not limited to) disclosure regarding our future earnings, financial position, operational and strategic initiatives, and developments in the healthcare industry. Forward-looking statements represent management’s expectations, based on currently available information, as to the outcome and timing of future events, but, by their nature, address matters that are indeterminate. They involve known and unknown risks, uncertainties and other factors, many of which we are unable to predict or control, that may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such factors include, but are not limited to, the risks described in the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report.

When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements in our Annual Report and in this report. Should one or more of the risks and uncertainties described in our Annual Report or this report occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statement. We specifically disclaim any obligation to update any information contained in a forward-looking statement or any forward-looking statement in its entirety except as required by law.

All forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.

### SOURCES OF REVENUE FOR OUR HOSPITAL OPERATIONS AND OTHER SEGMENT

We earn revenues for patient services from a variety of sources, primarily managed care payers and the federal Medicare program, as well as state Medicaid programs, indemnity-based health insurance companies and uninsured patients (that is, patients who do not have health insurance and are not covered by some other form of third-party arrangement).

The following table shows the sources of net patient service revenues less implicit price concessions for our hospitals and related outpatient facilities, expressed as percentages of net patient service revenues less implicit price concessions from all sources:

| Net Patient Service Revenues Less Implicit Price Concessions from: | Three Months Ended March 31, 2019 | 2018 | Increase (Decrease)(1) |
| --- | ---: | ---: | ---: |
| Medicare | 21.2% | 21.5% | (0.3)% |
| Medicaid | 8.8% | 8.8% | —% |
| Managed care(2) | 65.7% | 65.0% | 0.7% |
| Uninsured | —% | 1.0% | (1.0)% |
| Indemnity and other | 4.3% | 3.7% | 0.6% |

(1) The change is the difference between the 2019 and 2018 percentages shown.

(2) Includes Medicare and Medicaid managed care programs.

Our payer mix on an admissions basis for our hospitals and related outpatient facilities, expressed as a percentage of total admissions from all sources, is shown below:

| Admissions from: | Three Months Ended March 31, 2019 | 2018 | Increase (Decrease)(1) |
| --- | ---: | ---: | ---: |
| Medicare | 26.1% | 26.9% | (0.8)% |
| Medicaid | 6.0% | 6.2% | (0.2)% |
| Managed care(2) | 59.7% | 59.1% | 0.6% |
| Charity and uninsured | 5.7% | 5.4% | 0.3% |
| Indemnity and other | 2.5% | 2.4% | 0.1% |

(1) The change is the difference between the 2019 and 2018 percentages shown.

(2) Includes Medicare and Medicaid managed care programs.

### GOVERNMENT PROGRAMS

The Centers for Medicare and Medicaid Services, an agency of the U.S. Department of Health and Human Services (“HHS”), is the single largest payer of healthcare services in the United States. Approximately 58 million individuals rely on healthcare benefits through Medicare, and approximately 73 million individuals are enrolled in Medicaid and the Children’s Health Insurance Program (“CHIP”). These three programs are authorized by federal law and administered by the Centers for Medicare and Medicaid Services (“CMS”). Medicare is a federally funded health insurance program primarily for individuals 65 years of age and older, as well as certain younger people with certain disabilities and conditions, and is provided without regard to income or assets. Medicaid is administered by the states and is jointly funded by the federal government and state governments. Medicaid is the nation’s main public health insurance program for people with low incomes and is the largest source of health coverage in the United States. The CHIP, which is also administered by the states and jointly funded, provides health coverage to children in families with incomes too high to qualify for Medicaid, but too low to afford private coverage. Unlike Medicaid, the CHIP is limited in duration and requires the enactment of reauthorizing legislation. During the three months ended March 31, 2018, separate pieces of legislation were enacted extending CHIP funding for a total of ten years from federal fiscal year (“FFY”) 2018 (which began on October 1, 2017) through FFY 2027.

### Medicare

Medicare offers its beneficiaries different ways to obtain their medical benefits. One option, the Original Medicare Plan (which includes “Part A” and “Part B”), is a fee-for-service payment system. The other option, called Medicare Advantage (sometimes called “Part C” or “MA Plans”), includes health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”), private fee-for-service Medicare special needs plans and Medicare medical savings account plans. The major components of our net patient service revenues from continuing operations of the hospitals and related outpatient facilities in our Hospital Operations and other segment for services provided to patients enrolled in the Original Medicare Plan for the three months ended March 31, 2019 and 2018 are set forth in the following table:

| Revenue Descriptions | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Medicare severity-adjusted diagnosis-related group — operating | $404 | $424 |
| Medicare severity-adjusted diagnosis-related group — capital | 36 | 38 |
| Outliers | 23 | 27 |
| Outpatient | 190 | 194 |
| Disproportionate share | 59 | 58 |
| Other(1) | 46 | 41 |
| **Total Medicare net patient service revenues** | **$758** | **$782** |

(1) The other revenue category includes Medicare Direct Graduate Medical Education and Indirect Medical Education (“IME”) revenues, IME revenues earned by our children’s hospitals (one of which we divested in 2018) under the Children’s Hospitals Graduate Medical Education Payment Program administered by the Health Resources and Services Administration of HHS, inpatient psychiatric units, inpatient rehabilitation units, other revenue adjustments, and adjustments to the estimates for current and prior-year cost reports and related valuation allowances.

A general description of the types of payments we receive for services provided to patients enrolled in the Original Medicare Plan is provided in our Annual Report. Recent regulatory and legislative updates to the terms of these payment systems and their estimated effect on our revenues can be found under “Regulatory and Legislative Changes” below.

### Medicaid

Medicaid programs and the corresponding reimbursement methodologies are administered by the states and vary from state to state and from year to year. Estimated revenues under various state Medicaid programs, including state-funded managed care Medicaid programs, constituted approximately 19.0% and 19.2% of total net patient service revenues less implicit price concessions of our acute care hospitals and related outpatient facilities for the three months ended March 31, 2019 and 2018, respectively. We also receive disproportionate share hospital (“DSH”) and other supplemental revenues under various state Medicaid programs. For the three months ended March 31, 2019 and 2018, our total Medicaid revenues attributable to DSH and other supplemental revenues were approximately $199 million and $220 million, respectively. The 2019 period included $64 million related the Michigan provider fee program, $65 million from the California provider fee program, $41 million related to Medicaid DSH programs in multiple states, $26 million related to the Texas 1115 waiver program, and $3 million from a number of other state and local programs.

Several states in which we operate face budgetary challenges that have resulted, and likely will continue to result, in reduced Medicaid funding levels to hospitals and other providers. Because most states must operate with balanced budgets, and the Medicaid program is generally a significant portion of a state’s budget, states can be expected to adopt or consider adopting future legislation designed to reduce or not increase their Medicaid expenditures. In addition, some states delay issuing Medicaid payments to providers to manage state expenditures. As an alternative means of funding provider payments, many of the states in which we operate have adopted provider fee programs or received waivers under Section 1115 of the Social Security Act. Under a Medicaid waiver, the federal government waives certain Medicaid requirements, thereby giving states flexibility in the operation of their Medicaid program to allow states to test new approaches and demonstration projects to improve care. Generally the Section 1115 waivers are approved for a period of five years with an option to extend the waiver for three additional years. Continuing pressure on state budgets and other factors could result in future reductions to Medicaid payments, payment delays or additional taxes on hospitals.

Because we cannot predict what actions the federal government or the states may take under existing legislation and future legislation to address budget gaps, deficits, Medicaid expansion, provider fee programs or Medicaid Section 1115 waivers, we are unable to assess the effect that any such legislation might have on our business, but the impact on our future financial position, results of operations or cash flows could be material.

Medicaid and Managed Medicaid net patient service revenues from continuing operations recognized by the hospitals and related outpatient facilities in our Hospital Operations and other segment from Medicaid-related programs in the states in which our facilities are (or were, as the case may be) located, as well as from Medicaid programs in neighboring states, for the three months ended March 31, 2019 and 2018 are set forth in the following table. These revenues are presented net of provider assessments, which are reported as an offset reduction to fee-for-service Medicaid revenue.

| Hospital Location | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Alabama | $24 | $23 |
| Arizona | 34 | 43 |
| California | 226 | 219 |
| Florida | 52 | 61 |
| Georgia | — | (1) |
| Illinois | 5 | 31 |
| Massachusetts | 22 | 24 |
| Michigan | 187 | 183 |
| Pennsylvania | — | 9 |
| South Carolina | 14 | 13 |
| Tennessee | 8 | 10 |
| Texas | 108 | 84 |
|  | **$680** | **$699** |

Medicaid and Managed Medicaid revenues comprised 46% and 54%, respectively, of our Medicaid-related net patient service revenues from continuing operations recognized by the hospitals and related outpatient facilities in our Hospital Operations and other segment for both the three months ended March 31, 2019 and 2018.

### Regulatory and Legislative Changes

Material updates to the information set forth in our Annual Report about the Medicare and Medicaid payment systems are provided below.

#### Proposed Payment and Policy Changes to the Medicare Inpatient Prospective Payment Systems

Under Medicare law, CMS is required to annually update certain rules governing the inpatient prospective payment systems (“IPPS”). The updates generally become effective October 1, the beginning of the federal fiscal year. In April 2019, CMS issued Proposed Changes to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and Fiscal Year 2020 Rates (“Proposed IPPS Rule”). The Proposed IPPS Rule includes the following proposed payment and policy changes:

- A market basket increase of 3.2% for Medicare severity-adjusted diagnosis-related group (“MS-DRG”) operating payments for hospitals reporting specified quality measure data and that are meaningful users of electronic health record (“EHR”) technology (hospitals that do not report specified quality measure data and/or are not meaningful users of EHR technology will receive a reduced market basket increase); CMS is also proposing certain adjustments to the 3.2% market basket increase that result in a net operating payment update of 3.2% (before budget neutrality adjustments), including:
- A multifactor productivity reduction required by the ACA of 0.5%; and
- A 0.5% increase required under the Medicare Access and CHIP Reauthorization Act of 2015;
- Updates to the three factors used to determine the amount and distribution of Medicare uncompensated care disproportionate share (“UC-DSH”) payments; in addition to adjusting the UC-DSH amounts, CMS is proposing to base the distribution of the UC-DSH amounts on uncompensated care costs reported by hospitals in the 2015 cost reports, which reflects changes to the calculation of a hospital’s share of the UC-DSH amounts by: (1) removing low income days; and (2) using a single year of uncompensated care cost in lieu of the three-year averaging methodology used in recent years;
- A 0.96% net increase in the capital federal MS-DRG rate;
- An increase in the cost outlier threshold from $25,769 to $26,994; and
- Changes in the calculation of the wage index to address disparities between hospitals in high and low wage index areas that include:
- Increasing the wage index for hospitals with a wage index below the 25th percentile, and decreasing the wage index for hospitals with a wage index above the 75th percentile; and
- A refinement to the calculation of the “rural floor” wage index.

According to CMS, the combined impact of the payment and policy changes in the Proposed IPPS Rule for operating costs will yield an average 3.4% increase in Medicare operating MS-DRG fee-for-service (“FFS”) payments for hospitals in large urban areas (populations over one million), and an average 3.6% increase in operating MS-DRG FFS payments for proprietary hospitals in FFY 2020. We estimate that all of the payment and policy changes affecting operating MS-DRG payments, including those affecting Medicare DSH amounts, will result in an estimated 1.1% increase in our annual Medicare FFS IPPS payments, which yields an estimated increase of approximately $22 million. The Proposed IPPS Rule is subject to a 60-day comment period, and the final FFY 2020 IPPS payment and policy changes must be issued 60 days prior to the effective date. Because of the uncertainty associated with various factors that may influence our future IPPS payments by individual hospital, including legislative or legal actions, admission volumes, length of stay and case mix, as well as potential changes to the proposed rule, we cannot provide any assurances regarding our estimate of the impact of the proposed payment and policy changes.

#### Payment and Policy Changes to the Medicare Outpatient Prospective Payment and Ambulatory Surgery Center Payment Systems

On November 2, 2018, CMS released Changes to the Hospital Outpatient Prospective Payment System (“OPPS”) and Ambulatory Surgical Center (“ASC”) Payment System for calendar year (“CY”) 2019 (“Final OPPS/ASC Rule”). The Final OPPS/ASC Rule includes the following payment and policy changes:

- An estimated net increase of 1.35% for the OPPS rates based on an estimated market basket increase of 2.9% reduced by market basket index and multifactor productivity reductions required by the ACA of 0.75% and 0.8%, respectively;
- A transition over a two year period to the MPFS rates for the payment of clinic/office visits provided at off-campus, hospital-based departments that are currently paid under the OPPS (this payment reduction will not be made in a budget-neutral manner and will result in a reduction of approximately 0.6% to total CY 2019 OPPS payments);
- A 2.1% increase to the ASC payment rates; and
- A revision to the definition of “surgery” in the ASC payment system to account for certain “surgery-like” procedures, and the addition of 12 cardiac catheterization procedures and five related procedures to the ASC covered procedures list.

CMS projects that the combined impact of the payment and policy changes in the Final OPPS/ASC Rule will yield an average 0.6% increase in Medicare FFS OPPS payments for all hospitals, an average 0.7% increase in Medicare FFS OPPS payments for hospitals in large urban areas (populations over one million), and an average 1.0% increase in Medicare FFS OPPS payments for proprietary hospitals. Based on CMS’ estimates, the projected annual impact of the payment and policy changes in the Final OPPS/ASC Rule on our hospitals is an increase to Medicare FFS hospital outpatient revenues of approximately $7 million, which represents an increase of approximately 1.1%. Because of the uncertainty associated with various factors that may influence our future OPPS payments, including legislative or legal actions, volumes and case mix, we cannot provide any assurances regarding our estimate of the impact of the payment and policy changes.

The 340B program allows certain hospitals (i.e., only nonprofit organizations with specific federal designations and/or funding) to purchase separately-payable drugs at discounted rates from drug manufacturers. In the CY 2018 OPPS Final Rule, CMS reduced the payment for separately payable drugs purchased under the 340B program from average sale price (“ASP”) plus 6% to ASP minus 22.5%, and made a corresponding budget-neutral increase to payments to all hospitals for other drugs and services reimbursed under the OPPS. During the three months ended December 31, 2018, the U.S. District Court for the District of Columbia held that the adoption of the 340B payment adjustment in the CY 2018 OPPS Final Rule exceeded CMS’ statutory authority. Because of the complexity involved in determining equitable relief for the plaintiffs, the court requested the parties to submit briefs on the appropriate remedy. Although HHS has asked the U.S. Circuit Court of Appeals for the District of Columbia Circuit to review the lower court's decision, the government filed a motion in March 2019, asking the appellate court to hold the appeal in abeyance pending the district court’s entry of final judgment with regard to the remedy for hospitals. The district court’s remedy and/or an unfavorable outcome of any appeal could have an adverse effect on the Company’s net revenues and cash flows.

### PRIVATE INSURANCE

### Managed Care

We currently have thousands of managed care contracts with various HMOs and PPOs. HMOs generally maintain a full-service healthcare delivery network comprised of physician, hospital, pharmacy and ancillary service providers that HMO members must access through an assigned “primary care” physician. The member’s care is then managed by his or her primary care physician and other network providers in accordance with the HMO’s quality assurance and utilization review guidelines so that appropriate healthcare can be efficiently delivered in the most cost-effective manner. HMOs typically provide reduced benefits or reimbursement (or none at all) to their members who use non-contracted healthcare providers for non-emergency care.

PPOs generally offer limited benefits to members who use non-contracted healthcare providers. PPO members who use contracted healthcare providers receive a preferred benefit, typically in the form of lower co-pays, co-insurance or deductibles. As employers and employees have demanded more choice, managed care plans have developed hybrid products that combine elements of both HMO and PPO plans, including high-deductible healthcare plans that may have limited benefits, but cost the employee less in premiums.

The amount of our managed care net patient service revenues, including Medicare and Medicaid managed care programs, from our hospitals and related outpatient facilities during the three months ended March 31, 2019 and 2018 was $2.354 billion and $2.368 billion, respectively. Our top ten managed care payers generated 62% of our managed care net patient service revenues for the three months ended March 31, 2019. National payers generated 43% of our managed care net patient service revenues for the three months ended March 31, 2019. The remainder comes from regional or local payers. At March 31, 2019 and December 31, 2018, 62% and 61%, respectively, of our net accounts receivable for our Hospital Operations and other segment were due from managed care payers.

Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diem rates, discounted fee-for-service rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a patient-by-patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. We believe it is reasonably likely for there to be an approximately 3% increase or decrease in the estimated contractual allowances related to managed care plans. Based on reserves at March 31, 2019, a 3% increase or decrease in the estimated contractual allowance would impact the estimated reserves by approximately $15 million. Some of the factors that can contribute to changes in the contractual allowance estimates include: (1) changes in reimbursement levels for procedures, supplies and drugs when threshold levels are triggered; (2) changes in reimbursement levels when stop-loss or outlier limits are reached; (3) changes in the admission status of a patient due to physician orders subsequent to initial diagnosis or testing; (4) final coding of in-house and discharged-not-final-billed patients that change reimbursement levels; (5) secondary benefits determined after primary insurance payments; and (6) reclassification of patients among insurance plans with different coverage and payment levels. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues. In addition, on a corporate-wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.

We expect managed care governmental admissions to continue to increase as a percentage of total managed care admissions over the near term. However, the managed Medicare and Medicaid insurance plans typically generate lower yields than commercial managed care plans, which have been experiencing an improved pricing trend. Although we have benefited from solid year-over-year aggregate managed care pricing improvements for several years, we have seen these improvements moderate in recent years, and we believe the moderation could continue in future years. In the three months ended March 31, 2019, our commercial managed care net inpatient revenue per admission from the hospitals and related outpatient facilities in our Hospital Operations and other segment was approximately 98% higher than our aggregate yield on a per admission basis from government payers, including managed Medicare and Medicaid insurance plans.

### Indemnity

An indemnity-based agreement generally requires the insurer to reimburse an insured patient for healthcare expenses after those expenses have been incurred by the patient, subject to policy conditions and exclusions. Unlike an HMO member, a patient with indemnity insurance is free to control his or her utilization of healthcare and selection of healthcare providers.

### UNINSURED PATIENTS

Uninsured patients are patients who do not qualify for government programs payments, such as Medicare and Medicaid, do not have some form of private insurance and, therefore, are responsible for their own medical bills. A significant number of our uninsured patients are admitted through our hospitals’ emergency departments and often require high-acuity treatment that is more costly to provide and, therefore, results in higher billings, which are the least collectible of all accounts.

Self-pay accounts receivable, which include amounts due from uninsured patients, as well as co-pays, co-insurance amounts and deductibles owed to us by patients with insurance, pose significant collectability problems. At both March 31, 2019 and December 31, 2018, approximately 6% of our net accounts receivable for our Hospital Operations and other segment was self-pay. Further, a significant portion of our implicit price concessions relates to self-pay amounts. We provide revenue cycle management services through Conifer, which is subject to various statutes and regulations regarding consumer protection in areas including finance, debt collection and credit reporting activities. For additional information, see Item 1, Business — Regulations Affecting Conifer’s Operations, of Part I of our Annual Report.

Conifer has performed systematic analyses to focus our attention on the drivers of bad debt expense for each hospital. While emergency department use is the primary contributor to our implicit price concessions in the aggregate, this is not the case at all hospitals. As a result, we have increased our focus on targeted initiatives that concentrate on non-emergency department patients as well. These initiatives are intended to promote process efficiencies in collecting self‑pay accounts, as well as co-pay, co-insurance and deductible amounts owed to us by patients with insurance, that we deem highly collectible. We leverage a statistical-based collections model that aligns our operational capacity to maximize our collections performance. We are dedicated to modifying and refining our processes as needed, enhancing our technology and improving staff training throughout the revenue cycle process in an effort to increase collections and reduce accounts receivable.

Over the longer term, several other initiatives we have previously announced should also help address this challenge. For example, our *Compact with Uninsured Patients (“Compact”*) is designed to offer managed care-style discounts to certain uninsured patients, which enables us to offer lower rates to those patients who historically had been charged standard gross charges. Under the *Compact*, the discount offered to uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self-pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for self-pay accounts and other factors that affect the estimation process.

We also provide charity care to patients who are financially unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per-diem amount for services received, subject to a cap. Except for the per-diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid DSH payments. These payments are intended to mitigate our cost of uncompensated care, as well as reduced Medicaid funding levels. Generally, our method of measuring the estimated costs uses adjusted uninsured/charity patient days multiplied by selected operating expenses (which include salaries, wages and benefits, supplies and other operating expenses and which exclude the costs of our health plan businesses) per adjusted patient day. The adjusted uninsured/charity patient days represents actual uninsured/charity patient days adjusted to include uninsured/charity outpatient services by multiplying actual uninsured/charity patient days by the sum of gross uninsured/charity inpatient revenues and gross uninsured/charity outpatient revenues and dividing the results by gross uninsured/charity inpatient revenues. The following table shows our estimated costs (based on selected operating expenses) of caring for uninsured patients and charity care patients, as well as revenues attributable to Medicaid DSH and other supplemental revenues we recognized, in the three months ended March 31, 2019 and 2018.

| Estimated costs for: | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Uninsured patients | $158 | $146 |
| Charity care patients | 34 | 35 |
| Total | $192 | $181 |
| Medicaid DSH and other supplemental revenues | $199 | $220 |

### RESULTS OF OPERATIONS

The following two tables summarize our consolidated net operating revenues, operating expenses and operating income from continuing operations, both in dollar amounts and as percentages of net operating revenues, for the three months ended March 31, 2019 and 2018:

| Net operating revenues: | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Hospital Operations and other | $3,862 | $3,947 |
| Ambulatory Care | 480 | 498 |
| Conifer | 349 | 404 |
| Inter-segment eliminations | (146) | (150) |
| **Net operating revenues** | **4,545** | **4,699** |
| **Equity in earnings of unconsolidated affiliates** | **34** | **25** |
| Operating expenses: |  |  |
| Salaries, wages and benefits | 2,153 | 2,227 |
| Supplies | 741 | 774 |
| Other operating expenses, net | 1,074 | 1,060 |
| Electronic health record incentives | (1) | (1) |
| Depreciation and amortization | 208 | 204 |
| Impairment and restructuring charges, and acquisition-related costs | 19 | 47 |
| Litigation and investigation costs | 13 | 6 |
| Net losses (gains) on sales, consolidation and deconsolidation of facilities | 1 | (110) |
| **Operating income** | **$371** | **$517** |

|  | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Net operating revenues | 100.0% | 100.0% |
| Equity in earnings of unconsolidated affiliates | 0.7% | 0.5% |
| Operating expenses: |  |  |
| Salaries, wages and benefits | 47.3% | 47.3% |
| Supplies | 16.3% | 16.5% |
| Other operating expenses, net | 23.6% | 22.6% |
| Electronic health record incentives | —% | —% |
| Depreciation and amortization | 4.6% | 4.3% |
| Impairment and restructuring charges, and acquisition-related costs | 0.4% | 1.0% |
| Litigation and investigation costs | 0.3% | 0.1% |
| Net losses (gains) on sales, consolidation and deconsolidation of facilities | —% | (2.3)% |
| **Operating income** | **8.2%** | **11.0%** |

Total net operating revenues decreased by $154 million, or 3.3%, for the three months ended March 31, 2019 compared to the three months ended March 31, 2018. Hospital Operations and other net operating revenues decreased by $81 million, or 2.1%, for the three months ended March 31, 2019 compared to the same period in 2018, primarily due to the divestiture of hospitals since the 2018 period. Ambulatory Care net operating revenues decreased by $18 million, or 3.6%, for the three months ended March 31, 2019 compared to the prior-year period. The change in 2019 revenues was driven by a decrease of $49 million due to the sale of Aspen and a decrease of $15 million due to the deconsolidation of a facility, partially offset by an increase in same-facility net operating revenues of $21 million and an increase from acquisitions of $25 million. Conifer net operating revenues decreased by $55 million, or 13.6%, for the three months ended March 31, 2019 compared to the three months ended March 31, 2018. Conifer revenues from third-party customers, which are not eliminated in consolidation, decreased $51 million, or 20.1%, for the three months ended March 31, 2019 compared to the same period in 2018. Conifer revenues from third-party customers were negatively impacted by contract terminations related to the sales of customer hospitals, partially offset by the impact of the divestiture of former Tenet facilities that have now become third-party customers.

The following table shows selected operating expenses of our three reportable business segments. Information for our Hospital Operations and other segment is presented on a same-hospital basis, which includes the results of our same 65 hospitals operated throughout the three months ended March 31, 2019 and 2018. Our same-hospital information excludes the results of two Philadelphia-area hospitals, which we divested effective January 11, 2018, MacNeal Hospital, which we divested effective March 1, 2018, Des Peres Hospital, which we divested effective May 1, 2018, and three Chicago-area hospitals, which we divested effective January 28, 2019.

| Selected Operating Expenses Hospital Operations and other — Same-Hospital | Three Months Ended March 31, 2019 | 2018 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Salaries, wages and benefits | $1,799 | $1,747 | 3.0% |
| Supplies | 637 | 631 | 1.0% |
| Other operating expenses | 918 | 807 | 13.8% |
| Total | $3,354 | $3,185 | 5.3% |
| **Ambulatory Care** |  |  |  |
| Salaries, wages and benefits | $153 | $162 | (5.6)% |
| Supplies | 99 | 106 | (6.6)% |
| Other operating expenses | 82 | 92 | (10.9)% |
| Total | $334 | $360 | (7.2)% |
| **Conifer** |  |  |  |
| Salaries, wages and benefits | $185 | $225 | (17.8)% |
| Supplies | 1 | 2 | (50.0)% |
| Other operating expenses | 64 | 79 | (19.0)% |
| Total | $250 | $306 | (18.3)% |
| **Total** |  |  |  |
| Salaries, wages and benefits | $2,137 | $2,134 | 0.1% |
| Supplies | 737 | 739 | (0.3)% |
| Other operating expenses | 1,064 | 978 | 8.8% |
| Total | $3,938 | $3,851 | 2.3% |
| Rent/lease expense(1) |  |  |  |
| Hospital Operations and other | $59 | $56 | 5.4% |
| Ambulatory Care | 20 | 20 | —% |
| Conifer | 3 | 4 | (25.0)% |
| Total | $82 | $80 | 2.5% |

(1) Included in other operating expenses.

### RESULTS OF OPERATIONS BY SEGMENT

Our operations are reported in three segments:

- Hospital Operations and other, which is comprised of our acute care and specialty hospitals, ancillary outpatient facilities, urgent care centers, microhospitals and physician practices.
- Ambulatory Care, which is comprised of USPI’s ambulatory surgery centers, urgent care centers, imaging centers and surgical hospitals (and also included nine facilities in the United Kingdom until we divested Aspen effective August 17, 2018).
- Conifer, which provides healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems, as well as individual hospitals, physician practices, self-insured organizations, health plans and other entities.

### Hospital Operations and Other Segment

The following tables show operating statistics of our continuing operations hospitals and related outpatient facilities on a same-hospital basis, unless otherwise indicated, which includes the results of our same 65 hospitals operated throughout the three months ended March 31, 2019 and 2018. Our same-hospital information excludes the results of two Philadelphia-area hospitals, which we divested effective January 11, 2018, MacNeal Hospital, which we divested effective March 1, 2018, Des Peres Hospital, which we divested effective May 1, 2018, and three Chicago-area hospitals, which we divested effective January 28, 2019.

| Admissions, Patient Days and Surgeries | Same-Hospital Continuing Operations Three Months Ended March 31, 2019 | 2018 | Increase (Decrease) |  |
| --- | ---: | ---: | ---: | ---: |
| Number of hospitals (at end of period) | 65 | 65 | — | (1) |
| Total admissions | 173,470 | 173,684 | (0.1)% |  |
| Adjusted patient admissions(2) | 305,871 | 304,145 | 0.6% |  |
| Paying admissions (excludes charity and uninsured) | 163,632 | 164,239 | (0.4)% |  |
| Charity and uninsured admissions | 9,838 | 9,445 | 4.2% |  |
| Admissions through emergency department | 125,228 | 119,957 | 4.4% |  |
| Paying admissions as a percentage of total admissions | 94.3% | 94.6% | (0.3)% | (1) |
| Charity and uninsured admissions as a percentage of total admissions | 5.7% | 5.4% | 0.3% | (1) |
| Emergency department admissions as a percentage of total admissions | 72.2% | 69.1% | 3.1% | (1) |
| Surgeries — inpatient | 44,553 | 45,052 | (1.1)% |  |
| Surgeries — outpatient | 57,896 | 59,720 | (3.1)% |  |
| Total surgeries | 102,449 | 104,772 | (2.2)% |  |
| Patient days — total | 815,329 | 817,000 | (0.2)% |  |
| Adjusted patient days(2) | 1,408,053 | 1,405,568 | 0.2% |  |
| Average length of stay (days) | 4.70 | 4.70 | —% |  |
| Licensed beds (at end of period) | 17,221 | 17,246 | (0.1)% |  |
| Average licensed beds | 17,221 | 17,246 | (0.1)% |  |
| Utilization of licensed beds(3) | 52.6% | 52.6% | —% | (1) |

(1) The change is the difference between 2019 and 2018 amounts shown.

(2) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

(3) Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

| Outpatient Visits | Same-Hospital Continuing Operations Three Months Ended March 31, 2019 | 2018 | Increase (Decrease) |  |
| --- | ---: | ---: | ---: | ---: |
| Total visits | 1,696,094 | 1,730,018 | (2.0)% |  |
| Paying visits (excludes charity and uninsured) | 1,586,627 | 1,619,950 | (2.1)% |  |
| Charity and uninsured visits | 109,467 | 110,068 | (0.5)% |  |
| Emergency department visits | 651,852 | 663,722 | (1.8)% |  |
| Surgery visits | 57,896 | 59,720 | (3.1)% |  |
| Paying visits as a percentage of total visits | 93.5% | 93.6% | (0.1)% | (1) |
| Charity and uninsured visits as a percentage of total visits | 6.5% | 6.4% | 0.1% | (1) |

(1) The change is the difference between 2019 and 2018 amounts shown.

| Revenues | Same-Hospital Continuing Operations Three Months Ended March 31, 2019 | 2018 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Total segment net operating revenues(1) | $3,691 | $3,602 | 2.5% |
| **Selected revenue data – hospitals and related outpatient facilities** |  |  |  |
| Net patient service revenues(1)(2) | $3,559 | $3,494 | 1.9% |
| Net patient service revenue per adjusted patient admission(1)(2) | $11,636 | $11,488 | 1.3% |
| Net patient service revenue per adjusted patient day(1)(2) | $2,528 | $2,486 | 1.7% |

(1) Revenues are net of implicit price concessions.

(2) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

| Total Segment Selected Operating Expenses | Same-Hospital Continuing Operations Three Months Ended March 31, 2019 | 2018 | Increase (Decrease) |  |
| --- | ---: | ---: | ---: | ---: |
| Salaries, wages and benefits as a percentage of net operating revenues | 48.7% | 48.5% | 0.2% | (1) |
| Supplies as a percentage of net operating revenues | 17.3% | 17.5% | (0.2)% | (1) |
| Other operating expenses as a percentage of net operating revenues | 24.9% | 22.4% | 2.5% | (1) |

(1) The change is the difference between 2019 and 2018 amounts shown.

#### Revenues

Same-hospital net operating revenues increased $89 million, or 2.5%, during the three months ended March 31, 2019 compared to the three months ended March 31, 2018, primarily due to improved terms of our managed care contracts. Same-hospital admissions decreased 0.1% in the three months ended March 31, 2019 compared to the same period in 2018. Same-hospital outpatient visits decreased 2.0% in the three months ended March 31, 2019 compared to the prior-year period.

The following table shows the consolidated net accounts receivable by payer at March 31, 2019 and December 31, 2018:

|  | March 31, 2019 | December 31, 2018 |
| --- | ---: | ---: |
| Medicare | $252 | $229 |
| Medicaid | 76 | 74 |
| Net cost report settlements receivable and valuation allowances | 18 | 18 |
| Managed care | 1,584 | 1,467 |
| Self-pay uninsured | 47 | 47 |
| Self-pay balance after insurance | 103 | 94 |
| Estimated future recoveries | 151 | 148 |
| Other payers | 332 | 325 |
| Total Hospital Operations and other | 2,563 | 2,402 |
| Ambulatory Care | 183 | 191 |
| Total discontinued operations | (2) | 2 |
|  | **$2,744** | **$2,595** |

When we have an unconditional right to payment, subject only to the passage of time, the right is treated as a receivable. Patient accounts receivable, including billed accounts and certain unbilled accounts, as well as estimated amounts due from third-party payers for retroactive adjustments, are receivables if our right to consideration is unconditional and only the passage of time is required before payment of that consideration is due. Estimated uncollectable amounts are generally considered implicit price concessions that are a direct reduction to patient accounts receivable rather than allowance for doubtful accounts. Amounts related to services provided to patients for which we have not billed and that do not meet the conditions of unconditional right to payment at the end of the reporting period are contract assets. For our Hospital Operations and other segment, our contract assets consist primarily of services that we have provided to patients who are still receiving inpatient care in our facilities at the end of the reporting period. Our Hospital Operations and other segment’s contract assets are included in other current assets in the accompanying Condensed Consolidated Balance Sheet at March 31, 2019.

Collection of accounts receivable has been a key area of focus, particularly over the past several years. At March 31, 2019, our Hospital Operations and other segment collection rate on self-pay accounts was approximately 23.9%. Our self-pay collection rate includes payments made by patients, including co-pays, co-insurance amounts and deductibles paid by patients with insurance. Based on our accounts receivable from uninsured patients and co-pays, co-insurance amounts and deductibles owed to us by patients with insurance at March 31, 2019, a 10% decrease or increase in our self-pay collection rate, or approximately 2%, which we believe could be a reasonably likely change, would result in an unfavorable or favorable adjustment to patient accounts receivable of approximately $10 million. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients, the volume of patients through our emergency departments, the increased burden of co-pays and deductibles to be made by patients with insurance, and business practices related to collection efforts. These factors continuously change and can have an impact on collection trends and our estimation process.

Payment pressure from managed care payers also affects the collectability of our accounts receivable. We typically experience ongoing managed care payment delays and disputes; however, we continue to work with these payers to obtain adequate and timely reimbursement for our services. Our estimated Hospital Operations and other segment collection rate from managed care payers was approximately 98.2% at March 31, 2019.

We manage our implicit price concessions using hospital-specific goals and benchmarks such as (1) total cash collections, (2) point-of-service cash collections, (3) AR Days and (4) accounts receivable by aging category. The following tables present the approximate aging by payer of our net accounts receivable from the continuing operations of our Hospital Operations and other segment of $2.545 billion and $2.384 billion at March 31, 2019 and December 31, 2018, respectively, excluding cost report settlements receivable and valuation allowances of $18 million at both March 31, 2019 and December 31, 2018:

|  | March 31, 2019 Medicare | Medicaid | Managed Care | Indemnity, Self-Pay and Other | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| 0-60 days | 89% | 60% | 59% | 30% | 57% |
| 61-120 days | 5% | 17% | 16% | 19% | 15% |
| 121-180 days | 3% | 10% | 8% | 11% | 8% |
| Over 180 days | 3% | 13% | 17% | 40% | 20% |
| **Total** | **100%** | **100%** | **100%** | **100%** | **100%** |

|  | December 31, 2018 Medicare | Medicaid | Managed Care | Indemnity, Self-Pay and Other | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| 0-60 days | 89% | 51% | 60% | 29% | 56% |
| 61-120 days | 6% | 24% | 14% | 18% | 15% |
| 121-180 days | 2% | 10% | 8% | 11% | 8% |
| Over 180 days | 3% | 15% | 18% | 42% | 21% |
| **Total** | **100%** | **100%** | **100%** | **100%** | **100%** |

Conifer continues to implement revenue cycle initiatives to improve our cash flow. These initiatives are focused on standardizing and improving patient access processes, including pre-registration, registration, verification of eligibility and benefits, liability identification and collections at point-of-service, and financial counseling. These initiatives are intended to reduce denials, improve service levels to patients and increase the quality of accounts that end up in accounts receivable. Although we continue to focus on improving our methodology for evaluating the collectability of our accounts receivable, we may incur future charges if there are unfavorable changes in the trends affecting the net realizable value of our accounts receivable.

At March 31, 2019, we had a cumulative total of patient account assignments to Conifer of approximately $2.8 billion related to our continuing operations. These accounts have already been written off and are not included in our receivables or in the allowance for doubtful accounts; however, an estimate of future recoveries from all the accounts assigned to Conifer is determined based on our historical experience and recorded in accounts receivable.

Patient advocates from Conifer’s Medicaid Eligibility Program (“MEP”) screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs. Receivables from patients who are potentially eligible for Medicaid are classified as Medicaid pending, under the MEP, with appropriate contractual allowances recorded. Based on recent trends, approximately 96% of all accounts in the MEP are ultimately approved for benefits under a government program, such as Medicaid. The following table shows the approximate amount of accounts receivable in the MEP still awaiting determination of eligibility under a government program at March 31, 2019 and December 31, 2018 by aging category for the hospitals currently in the program:

|  | March 31, 2019 | December 31, 2018 |
| --- | ---: | ---: |
| 0-60 days | $73 | $72 |
| 61-120 days | 6 | 16 |
| 121-180 days | 1 | 3 |
| Over 180 days | 5 | 5 |
| **Total** | **$85** | **$96** |

#### Salaries, Wages and Benefits

Same-hospital salaries, wages and benefits as a percentage of net operating revenues increased by 20 basis points to 48.7% in the three months ended March 31, 2019 compared to the same period in 2018. Same-hospital net operating revenues increased 2.5% during the three months ended March 31, 2019 compared to the three months ended March 31, 2018, and same-hospital salaries, wages and benefits increased by 3% in the three months ended March 31, 2019 compared to the 2018 period. The change in same-hospital salaries, wages and benefits as a percentage of net operating revenues was primarily due to annual merit increases for certain of our employees, partially offset by decreased health benefits costs and the impact of previously announced workforce reductions as part of our enterprise-wide cost reduction initiatives. Salaries, wages and benefits expense for the three months ended March 31, 2019 and 2018 included stock-based compensation expense of $6 million and $5 million, respectively.

#### Supplies

Same-hospital supplies expense as a percentage of net operating revenues decreased by 20 basis points to 17.3% in the three months ended March 31, 2019 compared to the same period in 2018. Supplies expense was impacted by the benefits of the group-purchasing strategies and supplies-management services we utilize to reduce costs, partially offset by increased costs from certain higher acuity supply-intensive surgical services.

We strive to control supplies expense through product standardization, consistent contract terms and end-to-end contract management, improved utilization, bulk purchases, focused spending with a smaller number of vendors and operational improvements. The items of current cost reduction focus continue to be cardiac stents and pacemakers, orthopedics, implants, and high-cost pharmaceuticals.

#### Other Operating Expenses, Net

Same-hospital other operating expenses as a percentage of net operating revenues increased by 250 basis points to 24.9% in the three months ended March 31, 2019 compared to 22.4% in the same period in 2018. Same-hospital other operating expenses increased by $111 million, or 13.8%, for the three months ended March 31, 2019 compared to the three months ended March 31, 2018. The changes in other operating expenses included:

- increased malpractice expense of $42 million; and
- increased medical fees of $32 million.

Same-hospital malpractice expense in the 2019 period included an unfavorable adjustment of approximately $7 million from a 28 basis point decrease in the interest rate used to estimate the discounted present value of projected future malpractice liabilities. In the 2018 period, we recognized a favorable adjustment of approximately $10 million from a 35 basis point increase in the discounted present value of projected future malpractice liabilities.

### Ambulatory Care Segment

Our Ambulatory Care segment is comprised of USPI’s ambulatory surgery centers, urgent care centers, imaging centers and surgical hospitals. Our Ambulatory Care segment also included nine facilities in the United Kingdom until we divested Aspen effective August 17, 2018. USPI operates its surgical facilities in partnership with local physicians and, in many of these facilities, a healthcare system partner. We hold an ownership interest in each facility, with each being operated through a separate legal entity in most cases. USPI operates facilities on a day-to-day basis through management services contracts. Our sources of earnings from each facility consist of:

- management services revenues, computed as a percentage of each facility’s net revenues (often net of implicit price concessions); and
- our share of each facility’s net income (loss), which is computed by multiplying the facility’s net income (loss) times the percentage of each facility’s equity interests owned by USPI.

Our role as an owner and day-to-day manager provides us with significant influence over the operations of each facility. For many of the facilities our Ambulatory Care segment operates (108 of 334 facilities at March 31, 2019), this influence does not represent control of the facility, so we account for our investment in the facility under the equity method for an unconsolidated affiliate. USPI controls 226 of the facilities our Ambulatory Care segment operates, and we account for these investments as consolidated subsidiaries. Our net earnings from a facility are the same under either method, but the classification of those earnings differs. For consolidated subsidiaries, our financial statements reflect 100% of the revenues and expenses of the subsidiaries, after the elimination of intercompany amounts. The net profit attributable to owners other than USPI is classified within “net income available to noncontrolling interests.”

For unconsolidated affiliates, our consolidated statements of operations reflect our earnings in two line items:

- *equity in earnings of unconsolidated affiliates—*our share of the net income (loss) of each facility, which is based on the facility’s net income (loss) and the percentage of the facility’s outstanding equity interests owned by USPI; and
- *management and administrative services revenues, which is included in our net operating revenues—*income we earn in exchange for managing the day-to-day operations of each facility, usually quantified as a percentage of each facility’s net revenues less implicit price concessions.

Our Ambulatory Care segment operating income is driven by the performance of all facilities USPI operates and by USPI’s ownership interests in those facilities, but our individual revenue and expense line items contain only consolidated businesses, which represent 68% of those facilities. This translates to trends in consolidated operating income that often do not correspond with changes in consolidated revenues and expenses, which is why we disclose certain statistical and financial data on a pro forma systemwide basis that includes both consolidated and unconsolidated (equity method) facilities.

#### Results of Operations

The following table summarizes certain consolidated statements of operations items for the periods indicated:

| Ambulatory Care Results of Operations | Three Months Ended March 31, 2019 | 2018 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Net operating revenues | $480 | $498 | (3.6)% |
| Equity in earnings of unconsolidated affiliates | $31 | $27 | 14.8% |
| Salaries, wages and benefits | $153 | $162 | (5.6)% |
| Supplies | $99 | $106 | (6.6)% |
| Other operating expenses, net | $82 | $92 | (10.9)% |

Our Ambulatory Care net operating revenues decreased by $18 million, or 3.6%, for the three months ended March 31, 2019 compared to the three months ended March 31, 2018. The change in 2019 revenues was driven by a decrease of $49 million due to the sale of Aspen and a decrease of $15 million due to the deconsolidation of a facility, partially offset by an increase in same-facility net operating revenues of $21 million and an increase from acquisitions of $25 million.

Salaries, wages and benefits expense decreased by $9 million, or 5.6%, for the three months ended March 31, 2019 compared to the three months ended March 31, 2018. The change was driven by a decrease of $18 million due to the sale of Aspen and a decrease of $4 million due to the deconsolidation of a facility, partially offset by an increase in same-facility salaries, wages and benefits expense of $7 million and an increase from acquisitions of $6 million.

Supplies expense decreased by $7 million, or 6.6%, for the three months ended March 31, 2019 compared to the three months ended March 31, 2018. The change was driven by a decrease of $11 million due to the sale of Aspen and a decrease of $4 million due to the deconsolidation of a facility, partially offset by an increase in same-facility supplies expense of $3 million and an increase from acquisitions of $5 million.

Other operating expenses decreased by $10 million, or 10.9%, for the three months ended March 31, 2019 compared to the three months ended March 31, 2018. The change was driven by a decrease of $13 million due to the sale of Aspen and a decrease of $3 million due to the deconsolidation of a facility, partially offset by an increase in same-facility other operating expenses of $2 million and an increase from acquisitions of $4 million.

#### Facility Growth

The following table summarizes the changes in our same-facility revenue year-over-year on a pro forma systemwide basis, which includes both consolidated and unconsolidated (equity method) facilities. While we do not record the revenues of unconsolidated facilities, we believe this information is important in understanding the financial performance of our Ambulatory Care segment because these revenues are the basis for calculating our management services revenues and, together with the expenses of our unconsolidated facilities, are the basis for our equity in earnings of unconsolidated affiliates.

| Ambulatory Care Facility Growth | Three Months Ended March 31, 2019 |
| --- | ---: |
| Net revenues | 4.2% |
| Cases | 0.9% |
| Net revenue per case | 3.3% |

#### Joint Ventures with Healthcare System Partners

USPI’s business model is to jointly own its facilities with local physicians and, in many of these facilities, a not-for-profit healthcare system partner. Accordingly, as of March 31, 2019, the majority of facilities in our Ambulatory Care segment are operated in this model.

| Ambulatory Care Facilities Facilities: | Three Months Ended March 31, 2019 |
| --- | ---: |
| With a healthcare system partner | 205 |
| Without a healthcare system partner | 129 |
| Total facilities operated | 334 |
| **Change from December 31, 2018** |  |
| Acquisitions | — |
| De novo | — |
| Dispositions/Mergers | (3) |
| Total decrease in number of facilities operated | (3) |

During the three months ended March 31, 2019, we acquired controlling interests in two facilities in which we already had an equity method investment. These multi-specialty surgery centers are located in California. We paid immaterial cash proceeds for the additional ownership interests. Both facilities are jointly owned with local physicians and healthcare system partner.

We also regularly engage in the purchase of equity interests with respect to our investments in unconsolidated affiliates and consolidated facilities that do not result in a change of control. These transactions are primarily the acquisitions of equity interests in ambulatory care facilities and the investment of additional cash in facilities that need capital for acquisitions, new construction or other business growth opportunities. During the three months ended March 31, 2019, we invested approximately $6 million in such transactions.

### Conifer Segment

Our Conifer segment generated net operating revenues of $349 million and $404 million during the three months ended March 31, 2019 and 2018, respectively, a portion of which was eliminated in consolidation as described in Note 19 to the accompanying Condensed Consolidated Financial Statements. Conifer revenues from third-party customers, which are not eliminated in consolidation, decreased $51 million, or 20.1%, for the three months ended March 31, 2019 compared to the three months ended March 31, 2018. Conifer revenues from third-party customers were negatively impacted by contract terminations related to the sales of customer hospitals in the 2019 period compared to the 2018 period, as well as a $10 million contract termination payment in the 2018 period.

Salaries, wages and benefits expense for Conifer decreased $40 million, or 17.8%, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018, primarily due to the impact of previously announced workforce reductions as part of our enterprise-wide cost reduction initiatives.

Other operating expenses for Conifer decreased $15 million, or 19.0%, in the three months ended March 31, 2019 compared to the three months ended March 31, 2018, primarily due to the impact of our enterprise-wide cost reduction initiatives.

### Consolidated

#### Impairment and Restructuring Charges, and Acquisition-Related Costs

During the three months ended March 31, 2019, we recorded impairment and restructuring charges and acquisition-related costs of $19 million, consisting of $1 million of impairment charges, $16 million of restructuring charges and $2 million of acquisition-related costs. Restructuring charges consisted of $7 million of employee severance costs, $1 million of contract and lease termination fees, and $8 million of other restructuring costs. Acquisition-related costs consisted of $2 million of transaction costs. Our impairment charges and acquisition-related costs for the three months ended March 31, 2019 were comprised of $10 million from our Hospital Operations and other segment, $3 million from our Ambulatory Care segment and $6 million from our Conifer segment.

During the three months ended March 31, 2018, we recorded impairment and restructuring charges and acquisition-related costs of $47 million, consisting of $19 million of impairment charges, $25 million of restructuring charges and $3 million of acquisition-related costs. Impairment charges consisted primarily of $17 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for certain Chicago-area facilities and $2 million of other impairment charges. Restructuring charges consisted of $17 million of employee severance costs, $1 million of contract and lease termination fees, and $7 million of other restructuring costs. Acquisition-related costs consisted of $2 million of transaction costs and $1 million of acquisition integration charges. Our impairment and restructuring charges and acquisition-related costs for the three months ended March 31, 2018 were comprised of $41 million from our Hospital Operations and other segment, $1 million from our Ambulatory Care segment and $5 million from our Conifer segment.

#### Litigation and Investigation Costs

Litigation and investigation costs for the three months ended March 31, 2019 and 2018 were $13 million and $6 million, respectively.

#### Net Losses (Gains) on Sales, Consolidation and Deconsolidation of Facilities

During the three months ended March 31, 2019, we recorded net losses on sales, consolidation and deconsolidation of facilities of approximately $1 million, primarily comprised of a $7 million loss on the sale of our Chicago-area facilities, partially offset by $5 million of gains related to consolidation changes of certain USPI businesses due to ownership changes, as well as post-closing adjustments on several other recent divestitures.

During the three months ended March 31, 2018, we recorded net gains on sales, consolidation and deconsolidation of facilities of approximately $110 million, primarily comprised of a $98 million gain from the sale of MacNeal Hospital and other operations affiliated with the hospital in the Chicago area, and a gain of $13 million from the sales of our minority interests in four North Texas hospitals.

#### Interest Expense

Interest expense for the three months ended March 31, 2019 was $251 million compared to $255 million for the same period in 2018.

#### Income Tax Expense

During the three months ended March 31, 2019, we recorded income tax expense of $17 million in continuing operations on pre-tax income of $74 million compared to income tax expense of $70 million on pre-tax income of $260 million during the three months ended March 31, 2018. The reconciliation between the amount of recorded income tax expense (benefit) and the amount calculated at the statutory federal tax rate is shown in the following table:

|  | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Tax expense at statutory federal rate of 21% | $16 | $55 |
| State income taxes, net of federal income tax benefit | 3 | 10 |
| Tax attributable to noncontrolling interests | (17) | (18) |
| Nondeductible goodwill | — | 5 |
| Nontaxable gains | (1) | — |
| Stock-based compensation | (1) | 4 |
| Change in valuation allowance-interest expense limitation | 24 | 12 |
| Other items | (7) | 2 |
| **Income tax expense** | **$17** | **$70** |

#### Net Income Available to Noncontrolling Interests

Net income available to noncontrolling interests was $84 million for the three months ended March 31, 2019 compared to $92 million for the three months ended March 31, 2018. Net income available (loss attributable) to noncontrolling interests in the 2019 period was comprised of $(4) million related to our Hospital Operations and other segment, $68 million related to our Ambulatory Care segment and $20 million related to our Conifer segment. Of the portion related to our Ambulatory Care segment, $3 million was related to the minority interests in USPI.

### ADDITIONAL SUPPLEMENTAL NON-GAAP DISCLOSURES

The financial information provided throughout this report, including our Condensed Consolidated Financial Statements and the notes thereto, has been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). However, we use certain non-GAAP financial measures defined below in communications with investors, analysts, rating agencies, banks and others to assist such parties in understanding the impact of various items on our financial statements, some of which are recurring or involve cash payments. We use this information in our analysis of the performance of our business, excluding items we do not consider relevant to the performance of our continuing operations. In addition, we use these measures to define certain performance targets under our compensation programs.

“Adjusted EBITDA” is a non-GAAP measure defined by the Company as net income available (loss attributable) to Tenet Healthcare Corporation common shareholders before (1) the cumulative effect of changes in accounting principle, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating expense, net, (7) interest expense, (8) litigation and investigation (costs) benefit, net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization, and (12) income (loss) from divested operations and closed businesses (i.e., our health plan businesses). Litigation and investigation costs do not include ordinary course of business malpractice and other litigation and related expense.

The Company believes the foregoing non-GAAP measure is useful to investors and analysts because it presents additional information about the Company’s financial performance. Investors, analysts, Company management and the Company’s board of directors utilize this non-GAAP measure, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to peer companies, which utilize similar non-GAAP measures in their presentations. The human resources committee of the Company’s board of directors also uses certain non-GAAP measures to evaluate management’s performance for the purpose of determining incentive compensation. The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to GAAP and other non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance. The non-GAAP Adjusted EBITDA measure the Company utilizes may not be comparable to similarly titled measures reported by other companies. Because this measure excludes many items that are included in our financial statements, it does not provide a complete measure of our operating performance. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.

The following table shows the reconciliation of Adjusted EBITDA to net income available (loss attributable) to Tenet Healthcare Corporation common shareholders (the most comparable GAAP term) for the three months ended March 31, 2019 and 2018:

|  | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| **Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders** | **$(19)** | **$99** |
| Less: Net income available to noncontrolling interests | (84) | (92) |
| Income from discontinued operations, net of tax | 8 | 1 |
| Income from continuing operations | 57 | 190 |
| Income tax expense | (17) | (70) |
| Loss from early extinguishment of debt | (47) | (1) |
| Other non-operating income (expense), net | 1 | (1) |
| Interest expense | (251) | (255) |
| Operating income | 371 | 517 |
| Litigation and investigation costs | (13) | (6) |
| Net gains (losses) on sales, consolidation and deconsolidation of facilities | (1) | 110 |
| Impairment and restructuring charges, and acquisition-related costs | (19) | (47) |
| Depreciation and amortization | (208) | (204) |
| Loss from divested and closed businesses (i.e., the Company’s health plan businesses) | (1) | (1) |
| **Adjusted EBITDA** | **$613** | **$665** |
| **Net operating revenues** | **$4,545** | **$4,699** |
| **Less: Net operating revenues from health plans** | **—** | **6** |
| **Adjusted net operating revenues** | **$4,545** | **$4,693** |
| **Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders as a % of net operating revenues** | **(0.4)%** | **2.1%** |
| **Adjusted EBITDA as % of adjusted net operating revenues (Adjusted EBITDA margin)** | **13.5%** | **14.2%** |

### LIQUIDITY AND CAPITAL RESOURCES

### CASH REQUIREMENTS

There have been no material changes to our obligations to make future cash payments under contracts, such as debt and lease agreements, and under contingent commitments, such as standby letters of credit and minimum revenue guarantees, as disclosed in our Annual Report, except for the long-term debt transactions discussed in Note 7 to our accompanying Condensed Consolidated Financial Statements.

As part of our long-term objective to manage our capital structure, we may from time to time seek to retire, purchase, redeem or refinance some of our outstanding debt or equity securities subject to prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. These actions are part of our strategy to manage our leverage and capital structure over time, which is dependent on our total amount of debt, our cash and our operating results. We continue to seek further initiatives to increase the efficiency of our balance sheet by generating incremental cash, including by means of the sale of underutilized or inefficient assets.

At March 31, 2019, using the last 12 months of Adjusted EBITDA, our ratio of total long-term debt, net of cash and cash equivalent balances, to Adjusted EBITDA was 5.87x. We anticipate this ratio will fluctuate from quarter to quarter based on earnings performance and other factors, including the use of our revolving credit facility as a source of liquidity and acquisitions that involve the assumption of long-term debt. We intend to manage this ratio by following our business plan, managing our cost structure, possible asset divestitures and through other changes in our capital structure, including, if appropriate, the issuance of equity or convertible securities. Our ability to achieve our leverage and capital structure objectives is subject to numerous risks and uncertainties, many of which are described in the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report.

Our capital expenditures primarily relate to the expansion and renovation of existing facilities (including amounts to comply with applicable laws and regulations), equipment and information systems additions and replacements, introduction of new medical technologies, design and construction of new buildings, and various other capital improvements, as well as commitments to make capital expenditures in connection with acquisitions of businesses. Capital expenditures were $192 million and $143 million in the three months ended March 31, 2019 and 2018, respectively. We anticipate that our capital expenditures for continuing operations for the year ending December 31, 2019 will total approximately $650 million to $700 million, including $135 million that was accrued as a liability at December 31, 2018.

Interest payments, net of capitalized interest, were $158 million and $169 million in the three months ended March 31, 2019 and 2018, respectively.

Income tax refunds, net of tax payments, were approximately $9 million in the three months ended March 31, 2019 compared to $1 million in the three months ended March 31, 2018.

### SOURCES AND USES OF CASH

Our liquidity for the three months ended March 31, 2019 was primarily derived from net cash provided by operating activities, cash on hand and borrowings under our revolving credit facility. We had approximately $252 million of cash and cash equivalents on hand at March 31, 2019 to fund our operations and capital expenditures, and our borrowing availability under our credit facility was $808 million based on our borrowing base calculation at March 31, 2019.

Our primary source of operating cash is the collection of accounts receivable. As such, our operating cash flow is impacted by levels of cash collections, as well as levels of implicit price concessions, due to shifts in payer mix and other factors.

Net cash provided by operating activities was $10 million in the three months ended March 31, 2019 compared to $113 million in the three months ended March 31, 2018. Key factors contributing to the change between the 2019 and 2018 periods include the following:

- Decreased net cash of $25 million related to the California provider fee program due to the timing of payments from the state; and
- The timing of other working capital items.

Net cash used in investing activities was $139 million for the three months ended March 31, 2019 compared to net cash provided by investing activities of $373 million for the three months ended March 31, 2018. The primary reason for the decrease was proceeds from sales of facilities and other assets of $41 million in the 2019 period when we completed the sale of three hospitals and hospital-affiliated operations in the Chicago area compared to proceeds from sales of facilities and other assets of $425 million in the 2018 period when we completed the sale of hospitals, physician practices and related assets in the Philadelphia area and the sale of MacNeal Hospital and other operations affiliated with the hospital in the Chicago area. There was a decrease in proceeds from sales of marketable securities, long-term investments and other assets of $130 million in the 2019 period compared to the 2018 period primarily due to the sales of our minority interests in four North Texas hospitals in the 2018 period. Capital expenditures were $192 million and $143 million in the three months ended March 31, 2019 and 2018, respectively.

Net cash used in financing activities was $30 million and $123 million for the three months ended March 31, 2019 and 2018, respectively. The 2019 amount included the proceeds from the issuance of $1.5 billion aggregate principal amount of 6.250% senior secured second lien notes due 2027, as well as the payments for our purchases of $300 million aggregate principal amount of our outstanding 6.750% senior notes due 2020, $750 million aggregate principal amount of our outstanding 7.500% senior secured second lien notes due 2022, and $468 million aggregate principal amount of our outstanding 5.500% senior unsecured notes due 2019. The 2019 amount also included net borrowings under our credit facility of $190 million. The

2018 amount included our purchase of approximately $28 million aggregate principal amount of our 6.750% senior unsecured notes due 2023 and approximately $22 million aggregate principal amount of our 7.000% senior unsecured notes due 2025.

We record our equity securities and our debt securities classified as available-for-sale at fair market value. The

majority of our investments are valued based on quoted market prices or other observable inputs. We have no investments that

we expect will be negatively affected by the current economic conditions such that they will materially impact our financial

condition, results of operations or cash flows.

### DEBT INSTRUMENTS, GUARANTEES AND RELATED COVENANTS

*Senior Secured and Senior Unsecured Note Refinancing Transactions.* On February 5, 2019, we sold $1.5 billion aggregate principal amount of 6.250% senior secured second lien notes, which will mature on February 1, 2027 (the “2027 Senior Secured Second Lien Notes”). We will pay interest on the 2027 Senior Secured Second Lien Notes semi-annually in arrears on February 1 and August 1 of each year, which payments will commence on August 1, 2019. The proceeds from the sale of the 2027 Senior Secured Second Lien Notes were used, after payment of fees and expenses, together with cash on hand and borrowings under our Credit Agreement, to fund the redemption of all $300 million aggregate principal amount of our outstanding 6.750% senior notes due 2020 and all $750 million aggregate principal amount of our outstanding 7.500% senior secured second lien notes due 2022, as well as the repayment upon maturity of all $468 million aggregate principal amount of our outstanding 5.500% senior unsecured notes due March 1, 2019. In connection with the redemptions, we recorded a loss from early extinguishment of debt of approximately $47 million in the three months ended March 31, 2019, primarily related to the difference between the redemption prices and the par values of the notes, as well as the write-off of the associated unamortized issuance costs.

*Credit Agreement.* We have a senior secured revolving credit facility (as amended, the “Credit Agreement”) that provides, subject to borrowing availability, for revolving loans in an aggregate principal amount of up to $1 billion, with a $300 million subfacility for standby letters of credit. Obligations under the Credit Agreement, which has a scheduled maturity date of December 4, 2020, are guaranteed by substantially all of our domestic wholly owned hospital subsidiaries and are secured by a first-priority lien on the accounts receivable owned by us and the subsidiary guarantors. At March 31, 2019, we were in compliance with all covenants and conditions in our Credit Agreement. At March 31, 2019, we had $190 million of cash borrowings outstanding under the Credit Agreement subject to an interest rate of 3.66%, and we had $2 million of standby letters of credit outstanding. Based on our eligible receivables, $808 million was available for borrowing under the Credit Agreement at March 31, 2019.

*Letter of Credit Facility.* We have a letter of credit facility (as amended, the “LC Facility”) that provides for the issuance of standby and documentary letters of credit, from time to time, in an aggregate principal amount of up to $180 million (subject to increase to up to $200 million). The maturity date of the LC Facility is March 7, 2021. Obligations under the LC Facility are guaranteed and secured by a first-priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an equal ranking basis with our senior secured first lien notes. At March 31, 2019, we were in compliance with all covenants and conditions in our LC Facility. At March 31, 2019, we had $93 million of standby letters of credit outstanding under the LC Facility.

For additional information regarding our long-term debt and capital lease obligations, see Notes 6 and 7 to our accompanying Condensed Consolidated Financial Statements and Note 7 to the Consolidated Financial Statements included in our Annual Report.

### LIQUIDITY

From time to time, we expect to engage in additional capital markets, bank credit and other financing activities depending on our needs and financing alternatives available at that time. We believe our existing debt agreements provide flexibility for future secured or unsecured borrowings.

Our cash on hand fluctuates day-to-day throughout the year based on the timing and levels of routine cash receipts and disbursements, including our book overdrafts, and required cash disbursements, such as interest and income tax payments. Cash

flows from operating activities in the first quarter of the calendar year are usually lower than in subsequent quarters of the year,

primarily due to the timing of certain working capital requirements during the first quarter, including our annual 401(k)

matching contributions and annual incentive compensation payments. These fluctuations result in material intra-quarter net operating and investing uses of cash that have caused, and in the future could cause, us to use our Credit Agreement as a source of liquidity. We believe that existing cash and cash equivalents on hand, availability under our Credit Agreement, anticipated future cash provided by operating activities, and our investments in marketable securities of our captive insurance companies classified as noncurrent investments in our balance sheet should be adequate to meet our current cash needs. These sources of liquidity, in combination with any potential future debt incurrence, should also be adequate to finance planned capital expenditures, payments on the current portion of our long-term debt, payments to joint venture partners, including those related to put and call arrangements, and other presently known operating needs.

Long-term liquidity for debt service and other purposes will be dependent on the amount of cash provided by operating activities and, subject to favorable market and other conditions, the successful completion of future borrowings and potential refinancings. However, our cash requirements could be materially affected by the use of cash in acquisitions of businesses, repurchases of securities, the exercise of put rights or other exit options by our joint venture partners, and contractual commitments to fund capital expenditures in, or intercompany borrowings to, businesses we own. In addition, liquidity could be adversely affected by a deterioration in our results of operations, including our ability to generate sufficient cash from operations, as well as by the various risks and uncertainties discussed in this section and other sections of this report and in our Annual Report, including any costs associated with legal proceedings and government investigations.

We do not rely on commercial paper or other short-term financing arrangements nor do we enter into repurchase agreements or other short-term financing arrangements not otherwise reported in our period-end balance sheets. In addition, we do not have significant exposure to floating interest rates given that all of our current long-term indebtedness has fixed rates of interest.

### OFF-BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements that may have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for $132 million of standby letters of credit outstanding and guarantees at March 31, 2019.

### CRITICAL ACCOUNTING ESTIMATES

In preparing our Condensed Consolidated Financial Statements in conformity with GAAP, we must use estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable, given the particular circumstances in which we operate. Actual results may vary from those estimates.

We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different outcomes under different conditions or when using different assumptions.

Our critical accounting estimates have not changed from the description provided in our Annual Report.

## Market risk

As filed, 1,461 characters.

The following table presents information about certain of our market-sensitive financial instruments at March 31, 2019. The fair values were determined based on quoted market prices for the same or similar instruments. The average effective interest rates presented are based on the rate in effect at the reporting date. The effects of unamortized discounts and issue costs are excluded from the table.

*(Dollars in Millions)*

|  | Maturity Date, Years Ending December 31, 2019 | 2020 | 2021 | 2022 | 2023 | Thereafter | Total | Fair Value |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Fixed rate long-term debt | $158 | $2,428 | $1,973 | $2,824 | $1,897 | $5,685 | $14,965 | $15,411 |
| Average effective interest rates | 5.8% | 6.1% | 4.7% | 8.6% | 7.3% | 5.8% | 6.4% |  |
| Variable rate long-term debt | $— | $190 | $— | $— | $— | $— | $190 | $190 |
| Average effective interest rates | — | 3.7% | — | — | — | — | 3.7% |  |

We have no affiliation with partnerships, trusts or other entities (sometimes referred to as “special-purpose” or “variable-interest” entities) whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements by us. As a result, we have no exposure to the financing, liquidity, market or credit risks associated with such entities.

We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage or prepayment features.

## Controls and procedures

As filed, 1,204 characters.

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined by Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this report. The evaluation was performed under the supervision and with the participation of management, including our chief executive officer and chief financial officer. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the Exchange Act and the SEC rules thereunder.

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, except that additional controls were added for the recording and disclosure of right-of-use assets and liabilities related to operating leases.

## Risk factors

As filed, 137 characters.

There have been no material changes to the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2018.

Filed Apr 29, 2019.
Source: SEC EDGAR, the filing index for accession 0000070318-19-000024. Last ingested by Listed: Nov 15, 2026, 02:42 ET. No prices; not investment advice.
